LEXIVA Drug Patent Profile

Which patents cover Lexiva, and what generic alternatives are available?

Lexiva is a drug marketed by Viiv Hlthcare and is included in two NDAs.

The generic ingredient in LEXIVA is fosamprenavir calcium. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lexiva

A generic version of LEXIVA was approved as fosamprenavir calcium by MYLAN on April 15^th, 2016.

Summary for LEXIVA

US Patents:	0
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEXIVA

Paragraph IV (Patent) Challenges for LEXIVA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXIVA	Tablets	fosamprenavir calcium	700 mg	021548	1	2012-01-18

US Patents and Regulatory Information for LEXIVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	LEXIVA	fosamprenavir calcium	SUSPENSION;ORAL	022116-001	Jun 14, 2007		DISCN	Yes	No
Viiv Hlthcare	LEXIVA	fosamprenavir calcium	TABLET;ORAL	021548-001	Oct 20, 2003		DISCN	Yes	No

International Patents for LEXIVA

See the table below for patents covering LEXIVA around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	342113
Hungary	0101831
Norway	326265
United Kingdom	9815567

Supplementary Protection Certificates for LEXIVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0933372	C00933372/01	Switzerland		PRODUCT NAME: FOSAMPRENAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56706 17.03.2005
0933372	CA 2008 00027	Denmark
0933372	PA2008006	Lithuania		PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
0933372	300339	Netherlands		300339, 20180310, EXPIRES: 20190711

Investment and Fundamentals Analysis of Lexiva (Fosamprenavir)

Last updated: February 23, 2026

What is Lexiva's Market Position and Revenue Profile?

Lexiva (fosamprenavir) is a protease inhibitor marketed by GlaxoSmithKline (GSK) for human immunodeficiency virus (HIV) treatment. Approved by the FDA in 2003, it targets a niche segment of HIV therapy, primarily in combination regimens for treatment-naive and -experienced patients. As of 2022, Lexiva's sales have declined sharply due to patent expiration, generic competition, and evolving treatment guidelines.

In 2021, Lexiva's global branded revenue was approximately $30 million, a decrease from over $120 million in 2019. The drug accounts for less than 1% of GSK's total pharmaceutical income. Its competitive position becomes increasingly marginal as generics source alternative therapies.

How Have Patent and Regulatory Conditions Affected Lexiva?

Lexiva's patent protection expired in May 2019, allowing generic manufacturers to produce fosamprenavir. Patent litigation delayed generic entry until after the patent expiry date. As of 2022, multiple generics entered multiple markets, exerting downward pressure on price and volume.

Regulatory status remains stable, with no recent FDA alerts or safety issues. However, GSK has shifted focus toward new HIV agents and fixed-dose combinations (FDCs), limiting investment in Lexiva.

What Are the Key Market Drivers and Risks?

Drivers:

• Unique pharmacokinetics: once-daily administration
• Established safety profile in controlled settings
• Fixed-dose combination availability with other antiretrovirals

Risks:

• Patent expiry and generic competition reducing margins
• Evolving HIV treatment guidelines favoring integrase inhibitors (e.g., Dolutegravir)
• Limited pipeline or reformulation initiatives for Lexiva
• Declining market share as newer therapies dominate

How Competitive Is Lexiva Compared to Alternatives?

Attribute	Lexiva	Darunavir (Prezista)	Dolutegravir (Tivicay)
Market share (2022)	<1%	Estimated 10-12%	Estimated 15-20%
Patent status	Expired (2019)	Patented until 2024+	Patented until 2028+
Cost (average annual)	~$15,000 (brand)	~$20,000 (brand)	~$30,000 (brand)
Dosing flexibility	Once-daily, FDC available	Once-daily, FDC available	Once-daily

The market favors integrase strand transfer inhibitors (INSTIs) like dolutegravir due to superior efficacy, tolerability, and resistance profile, displacing protease inhibitors like Lexiva in first-line regimens.

What Is the Financial Outlook?

The decline in Lexiva's revenue is expected to continue as generic competition sustains. Its marginal contribution makes further investment unattractive. GSK's pipeline prioritizes next-generation HIV agents and long-acting injectables over reformulating Lexiva.

Wholesale price erosion: Based on recent generic entries, prices for fosamprenavir are likely to fall below $5,000 per year per patient in developed markets. Volume growth is constrained by small market share and competition.

What Are the Opportunities and Challenges for Investors?

Opportunities:

• Niche usage in salvage therapy where resistance precludes newer drugs
• Potential for niche marketing in developing markets with delayed generic penetration
• Development of fixed-dose combinations incorporating Lexiva

Challenges:

• Patent expiring and robust generic competition
• Competitive disadvantages against newer agents with better efficacy and tolerability
• Limited pipeline or innovation plans from GSK for Lexiva

Summary of Fundamental and Investment Considerations

• Revenue decline driven by patent expiry and generics
• Market share increasingly captured by newer INSTIs and boosted by guidelines favoring them
• Limited prospects for significant rebound without reformulation or new indications
• GSK's strategic focus has shifted away from Lexiva, reducing investment interest

Key Takeaways

• Lexiva's revenues have shrunk from a peak over $120 million (2019) to under $30 million (2021)
• Patent expiration in 2019 led to immediate generic competition
• Improved efficacy, tolerability, and dosing profiles favor newer HIV medications
• Investment prospects are limited; focus on salvage or niche markets might yield moderate returns
• The global HIV market is rapidly moving toward integrase inhibitors, diminishing Lexiva's relevance

Frequently Asked Questions

1. Will Lexiva regain market share?
No. The patent expiration, competitive landscape, and treatment guideline shifts favor newer agents. Little evidence supports a market share rebound.

2. Are there ongoing development efforts to reformulate Lexiva?
No. GSK has no publicly announced reformulation or pipeline initiatives for Lexiva since 2020.

3. What are the main competitors for Lexiva?
Darunavir and atazanavir, which have higher efficacy, better tolerability, and patent protection, dominate the protease inhibitor segment.

4. Is Lexiva viable in emerging markets?
Potentially. In countries with delayed patent enforcement or limited access to generics, Lexiva remains an option, albeit with minimal growth prospects.

5. What is the outlook for HIV drugs in the next five years?
The trend favors single-tablet regimens with integrase inhibitors. Investment focuses on long-acting injectables and novel agents targeting resistant HIV strains.

---

References

[1] GSK. (2022). Lexiva (fosamprenavir): Prescribing Information. Retrieved from https://gskpro.com

[2] IQVIA. (2022). HIV Market Data & Analytics.

[3] U.S. Food and Drug Administration. (2019). Patent and exclusivity status reports.

[4] World Health Organization. (2022). HIV Treatment Guidelines.